SelekTx Limited

SelekTx Limited is a biotechnology spin-out from University College Dublin that specializes in the discovery of a new class of highly selective biologic drugs known as Selektides. The company’s proprietary drug discovery platform utilizes patented libraries of novel biologics engineered from the human S100G protein to achieve precise, functional modulation of G Protein-coupled Receptors (GPCRs). By deploying selection strategies that involve natively expressed receptors in disease-associated cells, the platform aims to identify drug candidates with high affinity and selectivity, thereby reducing off-target side effects commonly associated with existing treatments for complex diseases. The company conducts research across laboratories in Dublin, Ireland, and Lund, Sweden, with a team focused on expanding these capabilities through computational analysis, high-throughput binding kinetics, and advanced structural visualization.

SelekTx serves pharmaceutical partners and investors by addressing significant unmet needs in the treatment of challenging conditions, such as Crohn’s disease and other disorders involving hard-to-drug proteins. The company actively seeks collaboration and licensing arrangements to advance its lead drug candidates from IND-enabling stages through clinical trials. Supported by funding from Enterprise Ireland and the Novo Nordisk Foundation, SelekTx has demonstrated successful preclinical results, including favorable pharmacokinetic profiles in in vivo efficacy studies. The company is currently targeting Series A financing to further its development programs and strengthen its preclinical pipeline, aiming to provide safer and more effective therapeutic alternatives in the biotechnology and pharmaceutical sectors.